United Kingdom · Question · Written question
UIN 110592
Idiopathic Pulmonary Fibrosis: Drugs
Original
Introduced
3 February 2026
Last action
12 February 2026 · Answer
Status
Answered
Sponsors
—
Subjects
Discovery layer
Source updated
12 February 2026
Summary
To ask the Secretary of State for Health and Social Care, whether his Department has an estimate of the earliest possible date Jascayd (nerandomilast) could be available to idiopathic pulmonary fibrosis patients.
This text is taken from the official record. PoliticalRepo does not editorialize.
Timeline
3 February 2026
Written question
To ask the Secretary of State for Health and Social Care, whether his Department has an estimate of the earliest possible date Jascayd (nerandomilast) could be available to idiopathic pulmonary fibrosis patients.
Source: Commons
12 February 2026
Answer
Nerandomilast does not currently have a United Kingdom marketing authorisation for use in the treatment of idiopathic pulmonary fibrosis. It is currently being evaluated by the National Institute for Health and Care Excellence (NICE) which makes recommend...
Source: Written answer
Votes
No vote records are attached yet.
Versions
No version snapshots stored. Document URLs remain at the source.
Documents
No documents linked.
Sponsors
- · Department of Health and Social Care · Answering body
Related records
No cross-record relationships stored yet.
Sources
PoliticalRepo is an index and interpretation layer, not the authoritative legal source.
- Official source: https://questions-statements.parliament.uk/written-questions/detail/2026-02-03/110592
- Open data entity: https://questions-statements-api.parliament.uk/api/writtenquestions/questions/1877894
- uk · wq-1877894 · source updated 12 February 2026